Biobanking for Biomarkers In Respiratory Disease, Allergic Diseases and/or Mast Cell Disorders
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorUniversity Hospital, Toulouse
About this trial
This study aims to build up a clinico-biological bank of samples from patients suspected of or suffering from allergic diseases (including asthma) or mast cell diseases in order to support future research in the field of allergic diseases. The biobank will help to identify new prognostic, diagnostic and/or predictive biomarkers.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients with a positive prick test or specific IgE regardless of the allergen
patients suspected of allergic pathology defined by the need to carry out a prick test or specific IgE or a food or drug reintroduction test as part of the treatment
patients with systemic or cutaneous mastocytosis according to the international classification8
patients with mast cell activation syndrome according to the international classification8
Disqualifiers
patients under legal protection, guardianship or curatorship
pregnant or breastfeeding women
Trial population
patients with respiratory disease or allergic disease or mast cell disorders
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Biobanking for Biomarkers In Respiratory Disease, Allergic diseases and/or mast cell disorders
constitution of a clinico-biological biobanking
Time frame
15 yearsSecondary outcomes
1
set of diagnostic and/or prognostic biomarkers
identify new set of diagnostic and/or prognostic biomarkers
Time frame
15 years2
set of predictive biomarkers
Identify new biomarkers and/or a set of predictive biomarkers of the severity of the pathology or the response to treatments.
Time frame
15 years3
Allergy markers exploration
Explore if allergy markers (including asthma) or mastocytosis can be found in samples other than blood (urine, skin, etc.).
Time frame
15 years4
Estimation of concordance of biomarkers
Estimate the concordance of the presence of known and/or newly identified biomarkers of interest in the biological sample(s) making up the clinical-biological bank with the clinical data collected.
Time frame
15 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov